VERTEX PHARMACEUTICALS INC / MA Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of $2.65 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-12-31 was $562.41M, a 63.13% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was $79.57M, a 40.34% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was $258.23M, a 6.98% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was $273.97M, a 22.72% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $2.65B, a 125.28% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was $1.17B, a 44.70% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $2.12B, a 3505.80% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $58.89M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-12-31 | $2.65B 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $562.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $641.98M derived: sum of 2 quarters · filed 2021-02-11 | $900.21M derived: sum of 3 quarters · filed 2021-02-11 | $1.17B 10-K · filed 2021-02-11 |
| 2019-09-30 | $79.57M 10-Q · filed 2019-10-31 | $337.79M derived: sum of 2 quarters · filed 2019-10-31 | $611.76M 10-Q · filed 2019-10-31 | $2.14B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $258.23M 10-Q · filed 2019-08-01 | $532.20M 10-Q · filed 2019-08-01 | $2.06B derived: sum of 3 quarters · filed 2021-02-11 | $2.19B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $273.97M 10-Q · filed 2019-05-01 | $1.80B derived: sum of 2 quarters · filed 2021-02-11 | $1.93B derived: sum of 3 quarters · filed 2021-02-11 | $2.17B derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $1.53B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $1.66B derived: sum of 2 quarters · filed 2021-02-11 | $1.90B derived: sum of 3 quarters · filed 2021-02-11 | $2.12B 10-K · filed 2021-02-11 |
| 2018-09-30 | $133.37M 10-Q · filed 2019-10-31 | $374.76M derived: sum of 2 quarters · filed 2019-10-31 | $598.01M 10-Q · filed 2019-10-31 | $713.75M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $241.39M 10-Q · filed 2019-08-01 | $464.64M 10-Q · filed 2019-08-01 | $580.38M derived: sum of 3 quarters · filed 2020-02-13 | $285.74M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $223.25M 10-Q · filed 2019-05-01 | $338.99M derived: sum of 2 quarters · filed 2020-02-13 | $44.35M derived: sum of 3 quarters · filed 2020-02-13 | $37.74M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $115.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$178.90M derived: sum of 2 quarters · filed 2020-02-13 | -$185.51M derived: sum of 3 quarters · filed 2020-02-13 | $58.89M 10-K · filed 2020-02-13 |
| 2017-09-30 | -$294.64M 10-Q · filed 2018-10-25 | -$301.25M derived: sum of 2 quarters · filed 2018-10-25 | -$56.85M 10-Q · filed 2018-10-25 | -$4.08M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | -$6.61M 10-Q · filed 2018-07-26 | $237.79M 10-Q · filed 2018-07-26 | $290.57M derived: sum of 3 quarters · filed 2019-02-13 | $250.58M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $244.40M 10-Q · filed 2018-04-27 | $297.18M derived: sum of 2 quarters · filed 2019-02-13 | $257.19M derived: sum of 3 quarters · filed 2019-02-13 | $222.54M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $52.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $12.79M derived: sum of 2 quarters · filed 2019-02-13 | -$21.86M derived: sum of 3 quarters · filed 2019-02-13 | -$64.68M 10-K · filed 2019-02-13 |
| 2016-09-30 | -$39.99M 10-Q · filed 2017-10-30 | -$74.63M derived: sum of 2 quarters · filed 2017-10-30 | -$117.46M 10-Q · filed 2017-10-30 | -$191.81M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$34.64M 10-Q · filed 2017-07-28 | -$77.47M 10-Q · filed 2017-07-28 | -$151.82M derived: sum of 3 quarters · filed 2018-02-15 | -$242.42M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$42.83M 10-Q · filed 2017-04-28 | -$117.18M derived: sum of 2 quarters · filed 2018-02-15 | -$207.78M derived: sum of 3 quarters · filed 2018-02-15 | -$431.27M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$74.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$164.95M derived: sum of 2 quarters · filed 2018-02-15 | -$388.44M derived: sum of 3 quarters · filed 2018-02-15 | -$587.27M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$90.60M 10-Q · filed 2016-10-31 | -$314.09M derived: sum of 2 quarters · filed 2016-10-31 | -$512.92M 10-Q · filed 2016-10-31 | -$694.01M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$223.49M 10-Q · filed 2016-08-01 | -$422.32M 10-Q · filed 2016-08-01 | -$603.41M derived: sum of 3 quarters · filed 2017-02-23 | -$772.29M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$198.83M 10-Q · filed 2016-05-03 | -$379.92M derived: sum of 2 quarters · filed 2017-02-23 | -$548.80M derived: sum of 3 quarters · filed 2017-02-23 | -$707.90M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$181.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$349.97M derived: sum of 2 quarters · filed 2017-02-23 | -$509.07M derived: sum of 3 quarters · filed 2017-02-23 | -$741.52M 10-K · filed 2017-02-23 |
| 2014-09-30 | -$168.88M 10-Q · filed 2015-10-30 | -$327.98M derived: sum of 2 quarters · filed 2015-10-30 | -$560.43M 10-Q · filed 2015-10-30 | -$744.74M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$159.11M 10-Q · filed 2015-08-04 | -$391.56M 10-Q · filed 2015-08-04 | -$575.86M derived: sum of 3 quarters · filed 2016-02-16 | -$703.84M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | -$232.45M 10-Q · filed 2015-05-04 | -$416.75M derived: sum of 2 quarters · filed 2016-02-16 | -$544.74M derived: sum of 3 quarters · filed 2016-02-16 | -$606.53M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | -$184.31M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$312.29M derived: sum of 2 quarters · filed 2016-02-16 | -$374.08M derived: sum of 3 quarters · filed 2016-02-16 | -$687.31M 10-K · filed 2016-02-16 |
| 2013-09-30 | -$127.98M 10-Q · filed 2014-11-06 | -$189.78M derived: sum of 2 quarters · filed 2014-11-06 | -$503.00M 10-Q · filed 2014-11-06 | -$581.21M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$61.79M 10-Q · filed 2014-07-31 | -$375.02M 10-Q · filed 2014-07-31 | -$453.23M derived: sum of 3 quarters · filed 2015-02-13 | -$479.44M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$313.23M 10-Q · filed 2014-05-05 | -$391.44M derived: sum of 2 quarters · filed 2015-02-13 | -$417.65M derived: sum of 3 quarters · filed 2015-02-13 | -$452.16M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$78.21M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$104.42M derived: sum of 2 quarters · filed 2015-02-13 | -$138.93M derived: sum of 3 quarters · filed 2015-02-13 | -$50.63M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$26.21M 10-Q · filed 2013-11-07 | -$60.72M derived: sum of 2 quarters · filed 2013-11-07 | $27.58M 10-Q · filed 2013-11-07 | $215.61M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$34.51M 10-Q · filed 2013-08-02 | $53.79M 10-Q · filed 2013-08-02 | $241.82M derived: sum of 3 quarters · filed 2014-02-11 | $470.04M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $88.30M 10-Q · filed 2013-05-08 | $276.33M derived: sum of 2 quarters · filed 2014-02-11 | $504.55M derived: sum of 3 quarters · filed 2014-02-11 | $305.16M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $188.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $416.25M derived: sum of 2 quarters · filed 2014-02-11 | $216.85M derived: sum of 3 quarters · filed 2014-02-11 | $41.19M 10-K · filed 2014-02-11 |
| 2011-09-30 | $228.21M 10-Q · filed 2012-11-06 | $28.82M derived: sum of 2 quarters · filed 2012-11-06 | -$146.84M 10-Q · filed 2012-11-06 | -$327.62M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$199.39M 10-Q · filed 2012-08-08 | -$375.05M 10-Q · filed 2012-08-08 | -$555.84M derived: sum of 3 quarters · filed 2013-03-01 | -$764.91M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$175.66M 10-Q · filed 2012-05-10 | -$356.44M derived: sum of 2 quarters · filed 2013-03-01 | -$565.52M derived: sum of 3 quarters · filed 2013-03-01 | -$765.00M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$180.78M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$389.86M derived: sum of 2 quarters · filed 2013-03-01 | -$589.34M derived: sum of 3 quarters · filed 2013-03-01 | -$755.05M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$209.08M 10-Q · filed 2010-10-28 | -$408.56M derived: sum of 2 quarters · filed 2011-08-09 | -$574.27M 10-Q · filed 2011-11-03 | -$733.44M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | -$199.48M 10-Q · filed 2011-08-09 | -$365.19M 10-Q · filed 2011-08-09 | -$524.36M derived: sum of 3 quarters · filed 2012-02-22 | -$674.46M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | -$165.71M 10-Q · filed 2011-05-06 | -$324.88M derived: sum of 2 quarters · filed 2012-02-22 | -$474.98M derived: sum of 3 quarters · filed 2012-02-22 | -$647.00M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | -$159.17M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$309.27M derived: sum of 2 quarters · filed 2012-02-22 | -$481.29M derived: sum of 3 quarters · filed 2012-02-22 | -$645.99M 10-K · filed 2012-02-22 |
| 2009-09-30 | -$150.10M 10-Q · filed 2010-10-28 | -$322.12M derived: sum of 2 quarters · filed 2010-10-28 | -$486.82M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | -$172.02M 10-Q · filed 2010-08-03 | -$336.72M 10-Q · filed 2010-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |